Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC

Therapeutic Drug Monitoring

Volumn 27, Issue 4, 2005, Pages 451-456

  Berry, David ^a,b   Millington, Christopher ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Medical Toxicology Unit   (United Kingdom)

Author keywords

Assay; HPLC; Pregabalin; Serum concentrations; TDM

Indexed keywords

ANTICONVULSIVE AGENT; PREGABALIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; PRECIPITATION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE; VALIDATION PROCESS;

ANTICONVULSANTS; CALIBRATION; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG STABILITY; DRUG THERAPY, COMBINATION; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HUMANS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TRIAZINES; TRINITROBENZENESULFONIC ACID; VALPROIC ACID;

EID: 23244466889     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000158874.54100.1a     Document Type: Article

References (22)

1. 2δ subunit of a calcium channel. J Biol Chem. 1996;271:5768-5776.
2. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236.
3. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280:107-110.
4. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086-1093.
5. 3H]glutamate from rat caudal trigeminal nucleus slices. Pain. 2001;93:191-196.
6. Deleted in proof.
7. Busch JA, Strand JA, Posvar EL, et al. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia. 1998;39(Suppl 6):58.
8. Turck D, Vollmer KO, Bockbrader H. Dose-linearity of the new anti-convulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol. 1989;36(Suppl):A310.
9. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276-281.
10. Bockbrader HN, Breslin EM, Uderwood BA, et al. Multiple-dose, dose-proportionality study of Neurontin® (Gabapentin) in healthy volunteers. Epilepsia. 1996;37(Suppl 5):159.
11. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-18.
12. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004;61:1-48.
13. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002;51:31-71.
14. Parke-Davis. Pregabalin Investigators Brochure. Ann Arbor, MI: Parke-Davis.
15. Bockbrader HN, Strand JC, Wesche DL, et al. Drug-interaction studies of pregabalin (CI-1008, PGB) in patients with epilepsy maintained on either valproate (VPA), lamotrigine (LTG), phenytoin (PHT), or carbamazepine (CBZ). Epilepsia. 2001;42(Suppl 7):86.
16. Bockbrader HN, Burger PJ, Kugler AR, et al. Population pharmacokinetic analyses of commonly prescribed antiepileptic drugs (AEDs) co-administered with pregabalin (PGB) in adult patients with refractory partial seizures. Epilepsia. 2001;42(Suppl 7):84.
17. Miller R, Frame B, Corrigan BW, et al. Mixed effects modelling of pregabalin response in patients with refractory partial seizures. Clin Pharmacol Ther. 2001;69:78.
18. French JA, Kugler AR, Garafalo EA, et al. Pregabalin dose-response in patients with partial seizures as evaluated in two add-on trials. Epilepsia. 2001;42(Suppl. 2):36.
19. http://www.fda.gov/cder/guidance/4252fnl.pdf; Accessed December 20, 2004.
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
21. Ben-Menachem E, Kugler AR. Pregabalin. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 901-904.
22. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomised, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.